Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jun;31(6):925–929. doi: 10.1128/aac.31.6.925

Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults.

B R Meyers, M H Mendelson, R G Deeter, E Srulevitch-Chin, M T Sarni, S Z Hirschman
PMCID: PMC284213  PMID: 3619425

Abstract

Two groups of 10 healthy ambulatory subjects, i.e., a group of 10 persons less than or equal to 30 years of age (mean age, 27.6 years) and a group of 10 persons greater than or equal to 65 years of age (mean age, 70 years), were randomized in a single-trial crossover design to receive 1 and 2 g of cefoperazone with a 1-week washout between doses. The elderly subjects had both decreased estimated creatinine clearances and decreased albumin concentrations in serum. Cefoperazone concentrations in serum of elderly persons were significantly higher at each interval from 30 min to 6 h for the 2-g dose. Compared with that in younger persons, the total clearance in elderly subjects was significantly lower for both the 1- and 2-g doses, the renal clearance was significantly lower for the 2-g dose, and the area under the curve was significantly higher for the 2-g dose in the elderly persons. The half-life at beta phase was higher in the elderly persons at both the 1- and 2-g doses but not significantly so. Changes in total clearance and area under the curve and higher levels in serum in the elderly persons suggest a longer duration of antimicrobial activity in this age group.

Full text

PDF
925

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bailey R. R., Peddie B., Blake E. Serum and urine concentrations of cefoperazone in severe chronic renal failure. Drugs. 1981;22 (Suppl 1):46–51. doi: 10.2165/00003495-198100221-00011. [DOI] [PubMed] [Google Scholar]
  2. Balant L., Dayer P., Rudhardt M., Allaz A. F., Fabre J. Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther. 1980;3(Spec Issue):50–59. [PubMed] [Google Scholar]
  3. Bawdon R. E., Hemsell D. L., Guss S. P. Comparison of cefoperazone and cefoxitin concentrations in serum and pelvic tissue of abdominal hysterectomy patients. Antimicrob Agents Chemother. 1982 Dec;22(6):999–1003. doi: 10.1128/aac.22.6.999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bender A. D., Post A., Meier J. P., Higson J. E., Reichard G., Jr Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci. 1975 Oct;64(10):1711–1713. doi: 10.1002/jps.2600641030. [DOI] [PubMed] [Google Scholar]
  5. Berger S. A., Zonszein J., Villamena P., Mittman N. Infectious diseases of the thyroid gland. Rev Infect Dis. 1983 Jan-Feb;5(1):108–122. doi: 10.1093/clinids/5.1.108. [DOI] [PubMed] [Google Scholar]
  6. Bolton W. K., Scheld W. M., Spyker D. A., Sande M. A. Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency. Antimicrob Agents Chemother. 1981 May;19(5):821–825. doi: 10.1128/aac.19.5.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Boscia J. A., Korzeniowski O. M., Snepar R., Kobasa W. D., Levison M. E., Kaye D. Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis. Antimicrob Agents Chemother. 1983 Mar;23(3):385–389. doi: 10.1128/aac.23.3.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buening M. K., Wold J. S., Israel K. S., Krammer R. B. Disulfiram-like reaction to beta-lactams. JAMA. 1981 May 22;245(20):2027–2027. [PubMed] [Google Scholar]
  9. Colaizzi P. A., Coniglio A. A., Poynor W. J., Vishniavsky N., Karnes H. T., Polk R. E. Comparative pharmacokinetics of two multiple-dose mezlocillin regimens in normal volunteers. Antimicrob Agents Chemother. 1986 Nov;30(5):675–678. doi: 10.1128/aac.30.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Friedman H., Greenblatt D. J. Rational therapeutic drug monitoring. JAMA. 1986 Oct 24;256(16):2227–2233. [PubMed] [Google Scholar]
  11. Hurwitz N. Predisposing factors in adverse reactions to drugs. Br Med J. 1969 Mar 1;1(5643):536–539. doi: 10.1136/bmj.1.5643.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jonsson M., Walder M. Pharmacokinetics of intravenous antibiotics in acutely ill elderly patients. Eur J Clin Microbiol. 1986 Dec;5(6):629–633. doi: 10.1007/BF02013286. [DOI] [PubMed] [Google Scholar]
  13. Jusko W. J., Gretch M. Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev. 1976;5(1):43–140. doi: 10.3109/03602537608995839. [DOI] [PubMed] [Google Scholar]
  14. Kovar M. G. Health of the elderly and use of health services. Public Health Rep. 1977 Jan-Feb;92(1):9–19. [PMC free article] [PubMed] [Google Scholar]
  15. LeBel M., Barbeau G., Vallee F., Bergeron M. G. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother. 1985 Nov;28(5):713–715. doi: 10.1128/aac.28.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ljungberg B., Nilsson-Ehle I. Pharmacokinetics of ceftazidime in elderly patients and young volunteers. Scand J Infect Dis. 1984;16(3):325–326. doi: 10.3109/00365548409070410. [DOI] [PubMed] [Google Scholar]
  17. Luderer J. R., Patel I. H., Durkin J., Schneck D. W. Age and ceftriaxone kinetics. Clin Pharmacol Ther. 1984 Jan;35(1):19–25. doi: 10.1038/clpt.1984.3. [DOI] [PubMed] [Google Scholar]
  18. Misra D. P., Loudon J. M., Staddon G. E. Albumin metabolism in elderly patients. J Gerontol. 1975 May;30(3):304–306. doi: 10.1093/geronj/30.3.304. [DOI] [PubMed] [Google Scholar]
  19. Moore R. D., Smith C. R., Lipsky J. J., Mellits E. D., Lietman P. S. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984 Mar;100(3):352–357. doi: 10.7326/0003-4819-100-3-352. [DOI] [PubMed] [Google Scholar]
  20. Naber K. G., Kees F., Grobecker H. Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):41–45. doi: 10.1093/jac/12.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  21. Neu H. C., Prince A. S. Interaction between moxalactam and alcohol. Lancet. 1980 Jun 28;1(8183):1422–1422. doi: 10.1016/s0140-6736(80)92693-8. [DOI] [PubMed] [Google Scholar]
  22. Ouslander J. G. Drug therapy in the elderly. Ann Intern Med. 1981 Dec;95(6):711–722. doi: 10.7326/0003-4819-95-6-711. [DOI] [PubMed] [Google Scholar]
  23. Rowe J. W., Andres R., Tobin J. D., Norris A. H., Shock N. W. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol. 1976 Mar;31(2):155–163. doi: 10.1093/geronj/31.2.155. [DOI] [PubMed] [Google Scholar]
  24. SENDROY J., Jr, CECCHINI L. P. Determination of human body surface area from height and weight. J Appl Physiol. 1954 Jul;7(1):1–12. doi: 10.1152/jappl.1954.7.1.1. [DOI] [PubMed] [Google Scholar]
  25. Sattler F. R., Colao D. J., Caputo G. M., Schoolwerth A. C. Cefoperazone for empiric therapy in patients with impaired renal function. Am J Med. 1986 Aug;81(2):229–236. doi: 10.1016/0002-9343(86)90256-1. [DOI] [PubMed] [Google Scholar]
  26. Schmucker D. L. Aging and drug disposition: an update. Pharmacol Rev. 1985 Jun;37(2):133–148. [PubMed] [Google Scholar]
  27. Shand D. G. Biological determinants of altered pharmacokinetics in the elderly. Gerontology. 1982;28 (Suppl 1):8–17. doi: 10.1159/000212568. [DOI] [PubMed] [Google Scholar]
  28. Srinivasan S., Francke E. L., Neu H. C. Comparative pharmacokinetics of cefoperazone and cefamandole. Antimicrob Agents Chemother. 1981 Feb;19(2):298–301. doi: 10.1128/aac.19.2.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Vestal R. E. Drug use in the elderly: a review of problems and special considerations. Drugs. 1978 Oct;16(4):358–382. doi: 10.2165/00003495-197816040-00004. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES